Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 16/20 | 0.81 |
| ▸ | NFKB2 | Q00653 | 16/20 | 0.81 |
| ▸ | RELA | Q04206 | 16/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7962069 | 0.90 | NFKB1 (0.83) | NFKB1NFKB2RELAKDM4EPKM | |
| SCHEMBL7975362 | 0.79 | NFKB1 (1.00) | NFKB1NFKB2RELAKDM4EPKM | |
| SCHEMBL7961876 | 0.79 | NFKB1 (0.76) | NFKB1NFKB2RELAKDM4EPKM | |
| SCHEMBL7975443 | 0.77 | NFKB1 (1.00) | NFKB1NFKB2RELAKDM4EPKM | |
| SCHEMBL7971965 | 0.75 | NFKB1 (1.00) | NFKB1NFKB2RELAKDM4EPKM | |
| SCHEMBL15808612 | 0.70 | NFKB1 (0.55) | NFKB1NFKB2RELA | |
| SCHEMBL7961832 | 0.69 | NFKB1 (1.00) | NFKB1NFKB2RELAABCB1 | |
| SCHEMBL22059555 | 0.69 | NFKB1 (0.62) | NFKB1NFKB2RELAMAPK1 | |
| SCHEMBL9058027 | 0.68 | NFKB1 (0.61) | NFKB1NFKB2RELAMAPK1 | |
| SCHEMBL7971958 | 0.68 | NFKB1 (0.77) | NFKB1NFKB2RELAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001072735-A2 | BENZOPYRANES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-10-04 | — | — | WO | disclosed |